semaglutide bmi 25 Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Weight Loss and Cardiovascular Events

Our Services Medications Semaglutide Tirzepatide Wegovy Future Medications Upcoming FDA Approval triple G or Retatrutide (GLP, GIP, and CGRP injection) Orforglipron (oral GLP-1) CariSema (amylin and GLP-1 injection) MariTide (GLP-1 monthly injection) Nimacimab (MASH/MAFLD treatment) Non-Surgical Weight Loss Safe, effective alternatives to surgical weight loss Medically supervised programs tailored to your needs Personalized treatment plans using evidence-based methods Support for sustainable, long-term weight loss Nutrition & Weight Loss Guidance to improve daily food intake Strategies to balance blood sugar levels Support for building healthy eating habits Nutrition-focused plans to enhance overall health Weight Loss Management Ongoing support throughout your weight loss journey Adjustments to your medical weight loss program as needed Lifestyle coaching for sustainable results Tools to help you maintain your goal weight confidently Healthcare, the way you want it

POTENTIAL SIDE EFFECTS BOOK NOW Headaches: Mild to moderate headaches may occur

Carcinog Ecotoxicol

It is FDA-approved under two brand names: Wegovy for chronic weight management and Ozempic for type 2 diabetes

Did my first injection on July 6